Please login to the form below
Teva and Novartis settle patent lawsuit
Teva Pharmaceuticals will settle patent litigation with Novartis involving Teva's US generic version of antiviral medication Famvir
Teva Pharmaceuticals, US, has signed an agreement with Novartis to settle patent litigation involving Teva's US generic version of the Novartis-developed antiviral medication Famvir (famciclovir).
The settlement includes all claims for patent infringement and damages.
Under the terms of the agreement, Israel-based Teva will make an undisclosed one-time payment to Novartis plus ongoing royalties on US sales of its product, which is used to treat herpes and shingles.
Teva is among the top 15 global pharmaceutical companies and is a leading generic pharmaceutical company. Teva launched the generic version of Famvir in September 2007.
Share
Related Hub content
Featured jobs
- Account Manager, Medical Communications and Marketing
-
£30, 000 – £40, 000 benefits and bonus
- Senior Account Manager, Medical Communications, London
-
Excellent package
- Senior Account Executive – Account Manager – Healthcare Advertis...
-
£32000 - £43000 Bonus Benfits
-
Creative/ Medical Writer
-
Circa £35, 000 With Benefits
- Scientific Director – Medical Communications
-
Salary TBC
-
Health Consultant - Brand Comms
-
Competitive Salary
- Home based, Senior Medical Writer, Medical Communications
-
Excellent package
-
Digital Account Director
-
Salary TBC
-
Senior Medical Writer
-
Salary TBC
- Scientific Director – Medical Communications - New York or Remot...
-
$100000 - $150000
- Freelance Senior Account Manager / Account Director - Healthcare...
-
£350-400 depending on experience
-
Account Director, Medical Education
-
Salary TBC
- Freelance AM/ AD Healthcare Advertising
-
£350-400 depending on experience
- Associate Director – Social Healthcare – London
-
HIGHLEY COMPETATIVE SALARY, BONUS &BENEFITS
- EU Head of Business Development and Client Service
-
Exceptional packge and bonus
- Science Writer, Healthcare Advertising Agency
-
£40, 000 - 45, 000 DOE benefits,
Subscribe to our email news alerts
- Roche, AbbVie hit by clinical hold for Venclexta in myeloma
- BMS defends Celgene buyout ahead of shareholder vote
- Apple Watch shows promise in heart study, but doctors sceptical
- Is May’s Brexit deal sinking after Speaker's procedural torpedo?
- Roche gets FDA nod for Tecentriq in small cell lung cancer
- New faces at 11 London, ramarketing and MSL
PMHub
Merrill Brink International
Merrill Brink International is a leading provider of life sciences, legal, financial, manufacturing and corporate language solutions for global companies....
Latest intelligence
- Genomics integration: can the NHS rise to the challenge?
- Experts gather to discuss the UK’s genomic landscape...
- “Brexit has been a catalyst for UK clinical research... it’s turbocharged change”
- The UK clinical trials environment has been transformed in recent years – but can it really buck Brexit’s risks and uncertainties?...
- The Future of Pharma sales: fast forward to 2029
- Change is inevitable, and necessary, for growth in business....
Quick links
Infographics
